Andere talen Inhibitor Therapeutics, Inc.

Aandelen

INTI

US45720M1053

Beurs gesloten - OTC Markets Andere beurzen 15:39:44 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0858 ^USD	+50,53%		+25,26%	-6,74%

29/03	Inhibitor Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	Introductie van Inhibitor Therapeutics, Inc. Kondigt Wetenschappelijke Adviesraad aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board	20/12
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	19/12
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	19/12
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	14/12
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University	13/12
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	18-10-23
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	29-08-23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11-08-23
INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	31-05-23
Inhibitor Therapeutics, Inc. Announces Board Changes	31-05-23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31-03-23
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31-03-23
INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	19-12-22
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	14-11-22
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22
Inhibitor Therapeutics : NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTIONS, PROPOSED SETTLEMENT AND SETTLEMENT HEARING - Form 8-K	15-09-22
INHIBITOR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	15-09-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Inhibitor Therapeutics, Inc.

Aandelen

INTI

US45720M1053

Andere talen

Filters